Study on Durvalumab and Tremelimumab for Limited Stage Small-Cell Lung Cancer After Chemoradiation

Inclusion Criteria

• Diagnosed with limited-stage small cell lung cancer (stage I-III).
• Completed 4 cycles of chemotherapy along with radiation therapy within 1 to 42 days before starting the study treatment. The chemotherapy must include platinum and IV etoposide, and the radiation therapy should be either 60-66 Gy over 6 weeks or 45 Gy over 3 weeks.
• Prophylactic cranial irradiation (PCI) may be given based on the doctor's decision and local practices, and must be completed 1 to 42 days before starting the study treatment.
• Cancer has not progressed after completing chemoradiation therapy.
• Expected to live at least 12 more weeks from the start of the study.
• In good general health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.

Exclusion Criteria

• Have extensive-stage small cell lung cancer.
• Have active or previously diagnosed autoimmune or inflammatory disorders.
• Have uncontrolled illnesses, such as interstitial lung disease.
• Have active infections, including tuberculosis, HIV, hepatitis B, or hepatitis C.
• Have received chemotherapy and radiation therapy separately, without any overlap.